Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Seminars in Immunopathology
Erschienen in: Seminars in Immunopathology 3/2008

01.07.2008 | Review

Genetics and immunopathology of chronic granulomatous disease

verfasst von: Marie José Stasia, Xing Jun Li

Erschienen in: Seminars in Immunopathology | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Chronic granulomatous disease (CGD) is a primary immunodeficiency syndrome characterized by a greatly increased susceptibility to severe fungal and bacterial infections. CGD results from a failure of the reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase enzyme in the patient’s phagocytes to produce superoxide. It is caused by mutations in any of four genes that encode the components of the NADPH oxidase. Investigation of CGD patients has identified the different subunits and the genes encoding them. Study of rare CGD variants has highlighted sequences involved in the structural stability of affected components or has provided valuable insights into their function in the oxidase activation mechanism. Functional and molecular CGD diagnosis tests are discussed in this review. Long-term antibiotic prophylaxis has been essential in fighting infections associated with CGD, but approaches based on hematopoietic stem cell transplantation and gene therapy offer great hope for the near future.
Literatur
1.
Baldridge CW, Gerard RW (1933) The extra respiration of phagocytosis. Am J Physiol 103:235–236
2.
Sbarra AJ, Karnovsky ML (1959) The biochemical basis of phagocytosis. I. Metabolic changes during the ingestion of particles by polymorphonuclear leukocytes. J Biol Chem 234:1355–1362 MedlinePubMed
3.
Selvaraj RJ, Sbarra AJ (1966) Relationship of glycolytic and oxidative metabolism to particle entry and destruction in phagocytosing cells. Nature 211:1272–1276 Medline DOI 10.​1038/​2111272a0 PubMedCrossRef
4.
Janeway CA, Craig J, Davidson M, Downey W, Gitlin D, Sullivan JC (1954) Hypergammaglobulinemia associated with severe, recurrent and chronic non-specific infection. Am J Dis Child 88:388–392
5.
Landing BH, Shirley HS (1957) A syndrome of recurrent infection and infiltration of viscera by pigmented lipid histiocytes. Pediatrics 20:431–438 MedlinePubMed
6.
Bridges RA, Berendes H, Good RA (1959) A fatal granulomatous disease of childhood: the clinical, pathological and laboratory features of a new syndrome. Am J Dis Child 97:387–408
7.
Quie PG, White JG, Holmes B, Good RA (1967) In vitro bactericidal capacity of human polymorphonuclear leukocytes: diminished activity in chronic granulomatous disease of childhood. J Clin Invest 46:668–679 MedlinePubMed
8.
9.
10.
11.
Rossi F, Zatti M (1964) Changes in the metabolic pattern of polymorphonuclear leucocytes during phagocytosis. Br J Exp Patho 45:548–559 Medline
12.
Shinagawa Y, Tanaka C, Teraoka A, Shinagawa Y (1966) A new cytochrome in neurophilic granules of rabbit leucocyte. J Biochem 59:622–624 MedlinePubMed
13.
Takikawa K, Ohta H (1966) On the nature of neutrophilic granules. Nippon Ketsueki Gakkai Zasshi. 29:571–577 MedlinePubMed
14.
15.
Teahan C, Rowe P, Parker P, Totty N, Segal AW (1987) The X-linked chronic granulomatous disease gene codes for the beta-chain of cytochrome b-245. Nature 327:720–721 Medline DOI 10.​1038/​327720a0 PubMedCrossRef
16.
Parkos CA, Allen RA, Cochrane CG, Jesaitis AJ (1987) Purified cytochrome b from human granulocyte plasma membrane is comprised of two polypeptides with relative molecular weights of 91,000 and 22,000. J Clin Invest 80:732–742 Medline DOI 10.​1172/​JCI113128 PubMedCrossRef
17.
Segal AW, Cross AR, Garcia RC, Borregaard N, Valerius NH, Soothill JF, Jones OT (1983) Absence of cytochrome b245 in chronic granulomatous disease. A multicenter European evaluation of its incidence and relevance. N Engl J Med 308:245–251 MedlinePubMed
18.
19.
Segal AW, Heyworth PG, Cockcroft S, Barrowman MM (1985) Stimulated neutrophils from patients with autosomal recessive chronic granulomatous disease fail to phosphorylate a Mr-44,000 protein. Nature 316:547–549 Medline DOI 10.​1038/​316547a0 PubMedCrossRef
20.
Umei T, Takeshige K, Minakami S (1987) NADPH-binding component of the superoxide-generating oxidase in unstimulated neutrophils and the neutrophils from the patients with chronic granulomatous disease. Biochem J 243:467–472 MedlinePubMed
21.
Curnutte JT, Kuver R, Scott PJ (1987) Activation of neutrophil NADPH oxidase in a cell-free system. Partial purification of components and characterization of the activation process. J Biol Chem 262:5563–5569 MedlinePubMed
22.
Abo A, Pick E, Hall A, Totty N, Teahan CG, Segal AW (1991) Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. Nature 353:668–670 Medline DOI 10.​1038/​353668a0 PubMedCrossRef
23.
24.
Ambruso DR, Knall C, Abell AN, Panepinto J, Kurkchubasche A, Thurman G, Gonzalez-Aller C, Hiester A, deBoer M, Harbeck RJ, Oyer R, Johnson GL, Roos D (2000) Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation. Proc Natl Acad Sci U S A 97:4654–4659 Medline DOI 10.​1073/​pnas.​080074897 PubMedCrossRef
25.
Williams DA, Tao W, Yang F, Kim C, Gu Y, Mansfield P, Levine JE, Petryniak B, Derrow CW, Harris C, Jia B, Zheng Y, Ambruso DR, Lowe JB, Atkinson SJ, Dinauer MC, Boxer L (2000) Dominant negative mutation of the hematopoietic-specific Rho GTPase, Rac2, is associated with a human phagocyte immunodeficiency. Blood 96:1646–1654PubMed
26.
27.
28.
29.
30.
Royer-Pokora B, Kunkel LM, Monaco AP, Goff SC, Newburger PE, Baehner RL, Cole FS, Curnutte JT, Orkin SH (1986) Cloning the gene for an inherited human disorder—chronic granulomatous disease—on the basis of its chromosomal location. Nature 322:32–38 Medline DOI 10.​1038/​322032a0 PubMedCrossRef
31.
Baehner RL, Kunkel LM, Monaco AP, Haines JL, Conneally PM, Palmer C, Heerema N, Orkin SH (1986) DNA linkage analysis of X chromosome-linked chronic granulomatous disease. Proc Natl Acad Sci U S A 83:3398–3401 Medline DOI 10.​1073/​pnas.​83.​10.​3398 PubMedCrossRef
32.
33.
34.
Volpp BD, Nauseef WM, Donelson JE, Moser DR, Clark RA (1989) Cloning of the cDNA and functional expression of the 47-kilodalton cytosolic component of human neutrophil respiratory burst oxidase. Proc Natl Acad Sci U S A 86:7195–7199 Medline DOI 10.​1073/​pnas.​86.​18.​7195 PubMedCrossRef
35.
Leto TL, Lomax KJ, Volpp BD, Nunoi H, Sechler JM, Nauseef WM, Clark RA, Gallin JI, Malech HL (1990) Cloning of a 67-kD neutrophil oxidase factor with similarity to a non-catalytic region of p60c-src. Science 248:727–730 Medline DOI 10.​1126/​science.​1692159 PubMedCrossRef
36.
Franke U, Hsieh CL, Foellmer BE, Lomax KJ, Malech HL, Leto TL (1990) Genes for two autosomal recessive forms of chronic granulomatous disease assigned to 1q25 (NCF2) and 7q11.23 (NCF1). Am J Hum Genet 47:483–492 Medline
37.
Dinauer MC, Pierce EA, Bruns GA, Curnutte JT, Orkin SH (1990) Human neutrophil cytochrome b light chain (p22-phox). Gene structure, chromosomal location, and mutations in cytochrome-negative autosomal recessive chronic granulomatous disease. J Clin Invest 86:1729–1737 Medline DOI 10.​1172/​JCI114898 PubMedCrossRef
38.
Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, Malech HL, Holland SM, Ochs H, Quie P, Buckley RH, Foster CB, Chanock SJ, Dickler H (2000) Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 79:155–169 Medline DOI 10.​1097/​00005792-200005000-00003 CrossRef
39.
Roos D, de Boer M, Kuribayashi F, Meischl C, Weening RS, Segal AW, Ahlin A, Nemet K, Hossle JP, Bernatowska-Matuszkiewicz E, Middleton-Price H (1996) Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Blood 87:1663–1681 MedlinePubMed
40.
Rae J, Newburger PE, Dinauer MC, Noack D, Hopkins PJ, Kuruto R, Curnutte JT (1998) X-linked chronic granulomatous disease: mutations in the CYBB gene encoding the gp91-phox component of respiratory-burst oxidase. Am J Hum Genet 62:1320–1331 Medline DOI 10.​1086/​301874 PubMedCrossRef
41.
Ishibashi F, Nunoi H, Endo F, Matsuda I, Kanegasaki S (2000) Statistical and mutational analysis of chronic granulomatous disease in Japan with special reference to gp91-phox and p22-phox deficiency. Hum Genet 106:473–481 Medline DOI 10.​1007/​s004390000288 PubMedCrossRef
42.
Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysinghe S, Krawczak M, Cooper DN (2003) Human gene mutation database (HGMD): 2003 update. Hum Mutat 21:577–581 Medline DOI 10.​1002/​humu.​10212 PubMedCrossRef
43.
44.
Cooper DN, Krawczak M (1991) Mechanisms of insertional mutagenesis in human genes causing genetic disease. Hum Genet 87:409–415 MedlinePubMed
45.
Heyworth PG, Curnutte JT, Rae J, Noack D, Roos D, van Koppen E, Cross AR (2001) Hematologically important mutations: X-linked chronic granulomatous disease (second update). Blood Cells Mol Dis 27:16–26 Medline DOI 10.​1006/​bcmd.​2000.​0347 PubMedCrossRef
46.
Krawczak M, Cooper DN (1991) Gene deletions causing human genetic disease: mechanisms of mutagenesis and the role of the local DNA sequence environment. Hum Genet 86:425–441 Medline DOI 10.​1007/​BF00194629 PubMedCrossRef
47.
Krawczak M, Thomas NS, Hundrieser B, Mort M, Wittig M, Hampe J, Cooper DN (2007) Single base-pair substitutions in exon-intron junctions of human genes: nature, distribution, and consequences for mRNA splicing. Hum Mutat 28:150–158 Medline DOI 10.​1002/​humu.​20400 PubMedCrossRef
48.
Cooper DN, Krawczak M (1990) The mutational spectrum of single base-pair substitutions causing human genetic disease: patterns and predictions. Hum Genet 85:55–74 Medline DOI 10.​1007/​BF00276326 PubMedCrossRef
49.
Stasia MJ, Bordigoni P, Floret D, Brion JP, Bost-Bru C, Michel G, Gatel P, Durant-Vital D, Voelckel MA, Li XJ, Guillot M, Maquet E, Martel C, Morel F (2005) Characterization of six novel mutations in the CYBB gene leading to different sub-types of X-linked chronic granulomatous disease. Hum Genet 116:72–82 Medline DOI 10.​1007/​s00439-004-1208-5 PubMedCrossRef
50.
51.
Stasia MJ, Brion JP, Boutonnat J, Morel F (2003) Severe clinical forms of cytochrome b-negative chronic granulomatous disease (X91-) in 3 brothers with a point mutation in the promoter region of CYBB. J Infect Dis 188:1593–1604 Medline DOI 10.​1086/​379035 PubMedCrossRef
52.
Newburger PE, Skalnik DG, Hopkins PJ, Eklund EA, Curnutte JT (1994) Mutation in the promoter region of the gene for gp91-phox in X-linked chronic granulomatous disease with decreased expression of cytochrome b558. J Clin Invest 94:1205–1211 Medline DOI 10.​1172/​JCI117437 PubMedCrossRef
53.
Woodman RC, Newburger PE, Anklesaria P, Erickson RW, Rae J, Cohen MS, Curnutte JT (1995) A new X-linked variant of chronic granulomatous disease characterized by the existence of a normal clone of respiratory burst-competent phagocytic cells. Blood 85:231−241 MedlinePubMed
54.
Suzuki S, Kumatori A, Haagen IA et al (1998) PU.1 as an essential activator for the expression of gp91phox gene in human peripheral neutrophils, monocytes, and B lymphocytes. Proc Natl Acad Sci U S A 95:6085–6090 Medline DOI 10.​1073/​pnas.​95.​11.​6085 PubMedCrossRef
55.
56.
Kuribayashi F, Kumatori A, Suzuki S, Nakamura M, Matsumoto T, Tsuji Y (1995) Human peripheral eosinophils have a specific mechanism to express gp91-phox, the large subunit of cytochrome b558. Biochem Biophys Res Commun 209:146–152 Medline DOI 10.​1006/​bbrc.​1995.​1482 PubMedCrossRef
57.
58.
59.
60.
Porter CD, Kuribayashi F, Parkar MH, Roos D, Kinnon C (1996) Detection of gp91-phox precursor protein in B-cell lines from patients with X-linked chronic granulomatous disease as an indicator for mutations impairing cytochrome b558 biosynthesis. Biochem J 315:571–575 MedlinePubMed
61.
Tsuda M, Kaneda M, Sakiyama T, Inana I, Owada M, Kiryu C, Shiraishi T, Kakinuma K (1998) A novel mutation at a probable heme-binding ligand in neutrophil cytochrome b558 in atypical X-linked chronic granulomatous disease. Hum Genet 103:377–381 Medline DOI 10.​1007/​s004390050836 PubMedCrossRef
62.
Fujii H, Finnegan MG, Miki T, Crouse BR, Kakinuma K, Johnson MK (1995) Spectroscopic identification of the axial ligation of cytochrome b558 in the NADPH oxidase of porcine neutrophils. FEBS Lett 377:345–348 Medline DOI 10.​1016/​0014-5793(95)01372-5 PubMedCrossRef
63.
Bolscher BG, de Boer M, de Klein A, Weening RS, Roos D (1991) Point mutations in the beta-subunit of cytochrome b558 leading to X-linked chronic granulomatous disease. Blood 77:2482–2487 MedlinePubMed
64.
DeLeo FR, Burritt JB, Yu L, Jesaitis AJ, Dinauer MC, Nauseef WM (2000) Processing and maturation of flavocytochrome b558 include incorporation of heme as a prerequisite for heterodimer assembly. J Biol Chem 275:13986–13993 Medline DOI 10.​1074/​jbc.​275.​18.​13986 PubMedCrossRef
65.
Bu-Ghanim HN, Segal AW, Keep NH, Casimir CM (1995) Molecular analysis in three cases of X91− variant chronic granulomatous disease. Blood 86:3575–3582 MedlinePubMed
66.
Curnutte JT (1995) Disorders of phagocyte function. In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, Silberstein LE (eds) Hematology: basic principles and practice. Churchill Livingstone, New York, p 792
67.
Roos D, de Boer M, Borregard N, Bjerrum OW, Valerius NH, Seger RA, Mühlebach T, Belohradsky BH, Weening RS (1992) Chronic granulomatous disease with partial deficiency of cytochrome b558 and incomplete respiratory burst: variants of the X-linked, cytochrome b558-negative form of the disease. J Leukoc Biol 51:164–171 MedlinePubMed
68.
Roesler J, Heyden S, Burdelski M, Schafer H, Kreth HW, Lehmann R, Paul D, Marzahn J, Gahr M, Rosen-Wolff A (1999) Uncommon missense and splice mutations and resulting biochemical phenotypes in German patients with X-linked chronic granulomatous disease. Exp Hematol 27:505–511 Medline DOI 10.​1016/​S0301-472X(98)00024-1 PubMedCrossRef
69.
Li XJ, Grunwald D, Mathieu J, Morel F, Stasia MJ (2005) Crucial role of two potential cytosolic regions of NOX2,191TSSTKTIRRS200 and 484DESQANHFAVHHDEEKD500, on NADPH oxidase activation. J Biol Chem 280:14962–14973 Medline DOI 10.​1074/​jbc.​M500226200 PubMedCrossRef
70.
Yoshida LS, Saruta F, Yoshikawa K, Tatsuzawa O, Tsunawaki S (1998) Mutation at histidine 338 of gp91(phox) depletes FAD and affects expression of cytochrome b558 of the human NADPH oxidase. J Biol Chem 273:27879–27886 Medline DOI 10.​1074/​jbc.​273.​43.​27879 PubMedCrossRef
71.
Ariga T, Sakiyama Y, Matsumoto S (1994) Two novel point mutations in the cytochrome b 558 heavy chain gene, detected in two Japanese patients with X-linked chronic granulomatous disease. Hum Genet 94:441 Medline DOI 10.​1007/​BF00201609 PubMedCrossRef
72.
73.
Stasia MJ (2007) The X+ chronic granulomatous disease as a fabulous model to study the NADPH oxidase complex activation. Med Sci (Paris) 23:526–532
74.
75.
Ariga T, Sakiyama Y, Tomizawa K, Imajoh-Ohmi S, Kanegasaki S, Matsumoto S (1993) A newly recognized point mutation in the cytochrome b558 heavy chain gene replacing alanine57 by glutamic acid, in a patient with cytochrome b positive X-linked chronic granulomatous disease. Eur J Pediatr 152:469–472 Medline DOI 10.​1007/​BF01955051 PubMedCrossRef
76.
Ariga T, Furuta H, Cho K, Sakiyama Y (1998) Genetic analysis of 13 families with X-linked chronic granulomatous disease reveals a low proportion of sporadic patients and a high proportion of sporadic carriers. Pediatr Res 44:85–92 Medline DOI 10.​1203/​00006450-199807000-00014 PubMedCrossRef
77.
Stasia MJ, Lardy B, Maturana A, Rousseau P, Martel C, Bordigoni P, Demaurex N, Morel F (2002) Molecular and functional characterization of a new X-linked chronic granulomatous disease variant (X91+) case with a double missense mutation in the cytosolic gp91phox C-terminal tail. Biochim Biophys Acta 1586:316–330 MedlinePubMed
78.
Zhen L, King AA, Xiao Y, Chanock SJ, Orkin SH, Dinauer MC (1993) Gene targeting of X chromosome-linked chronic granulomatous disease locus in a human myeloid leukemia cell line and rescue by expression of recombinant gp91phox. Proc Natl Acad Sci U S A 90:9832–9836 Medline DOI 10.​1073/​pnas.​90.​21.​9832 PubMedCrossRef
79.
Tucker KA, Lilly MB, Heck L Jr, Rado TA (1987) Characterization of a new human diploid myeloid leukemia cell line (PLB-985) with granulocytic and monocytic differentiating capacity. Blood 70:372–378 MedlinePubMed
80.
Bionda C, Li XJ, van Bruggen R, Eppink M, Roos D, Morel F, Stasia MJ (2004) Functional analysis of two-amino acid substitutions in gp91 phox in a patient with X-linked flavocytochrome b558-positive chronic granulomatous disease by means of transgenic PLB-985 cells. Hum Genet 115:418–427 Medline DOI 10.​1007/​s00439-004-1173-z PubMedCrossRef
81.
Dusi S, Nadalini KA, Donini M, Zentilin L, Wientjes FB, Roos D, Giacca M, Rossi F (1998) Nicotinamide–adenine dinucleotide phosphate oxidase assembly and activation in EBV-transformed B lymphoblastoid cell lines of normal and chronic granulomatous disease patients. J Immunol 161:4968–4974 MedlinePubMed
82.
Leusen JH, Meischl C, Eppink MH, Hilarius PM, de Boer M, Weening RS, Ahlin A, Sanders L, Goldblatt D, Skopczynska H, Bernatowska E, Palmblad J, Verhoeven AJ, van Berkel WJ, Roos D (2000) Four novel mutations in the gene encoding gp91-phox of human NADPH oxidase: consequences for oxidase assembly. Blood 95:666–673 MedlinePubMed
83.
Dinauer MC, Curnutte JT, Rosen H, Orkin SH (1989) A missense mutation in the neutrophil cytochrome b heavy chain in cytochrome-positive X-linked chronic granulomatous disease. J Clin Invest 84:2012–2016 Medline DOI 10.​1172/​JCI114393 PubMedCrossRef
84.
Segal AW, West I, Wientjes F, Nugent JH, Chavan AJ, Haley B, Garcia RC, Rosen H, Scrace G (1992) Cytochrome b-245 is a flavocytochrome containing FAD and the NADPH-binding site of the microbicidal oxidase of phagocytes. Biochem J 284:781–788 MedlinePubMed
85.
Taylor WR, Jones DT, Segal AW (1993) A structural model for the nucleotide binding domains of the flavocytochrome b-245 beta-chain. Protein Sci 2:1675–1685 MedlinePubMedCrossRef
86.
Li XJ, Fieschi F, Paclet MH, Grunwald D, Campion Y, Gaudin P, Morel F, Stasia MJ (2007) Leu505 of NOX2 is crucial in the NADPH-binding process during NADPH oxidase activation in phagocytes. J Leukoc Biol 81:238–249 Medline DOI 10.​1189/​jlb.​0905541 PubMedCrossRef
87.
Azuma H, Oomi H, Sasaki K, Kawabata I, Sakaino T, Koyano S, Suzutani T, Nunoi H, Okuno A (1995) A new mutation in exon 12 of the gp91-phox gene leading to cytochrome b-positive X-linked chronic granulomatous disease. Blood 85:3274–3277 MedlinePubMed
88.
89.
Leusen JH, de Boer M, Bolscher BG, Hilarius PM, Weening RS, Ochs HD, Roos D, Verhoeven AJ (1994) A point mutation in gp91-phox of cytochrome b558 of the human NADPH oxidase leading to defective translocation of the cytosolic proteins p47-phox and p67-phox. J Clin Invest 93:2120–2126 Medline DOI 10.​1172/​JCI117207 PubMedCrossRef
90.
Schapiro BL, Newburger PE, Klempner MS, Dinauer MC (1991) Chronic granulomatous disease presenting in a 69-year-old man. N Engl J Med 325:1786–1790 MedlinePubMed
91.
Yu L, Cross AR, Zhen L, Dinauer MC (1999) Functional analysis of NADPH oxidase in granulocytic cells expressing a delta488-497 gp91(phox) deletion mutant. Blood 94:2497–2504 MedlinePubMed
92.
Cross AR, Noack D, Rae J, Curnutte JT, Heyworth PG (2000) Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (first update). Blood Cells Mol Dis 26:561–565 Medline DOI 10.​1006/​bcmd.​2000.​0333 PubMedCrossRef
93.
Roos D, de Boer M, Köker MY, Dekker J, Singh-Gupta V, Ahlin A, Palmblad J, Sanal O, Kurenko-Deptuch M, Jolles S, Wolach B (2006) Chronic granulomatous disease caused by mutations other than the common GT deletion in NCF1, the gene encoding the p47phox component of the phagocyte NADPH oxidase. Hum Mutat 27:1218–1229 Medline DOI 10.​1002/​humu.​20413 PubMedCrossRef
94.
Chanock SJ, Roesler J, Chanock SJ, Roesler J, Zhan S, Hopkins P, Lee P, Barrett DT, Christensen BL, Curnutte JT, Görlach A (2000) Genomic structure of the human p47-phox (NCF1) gene. Blood Cells Mol Dis 26:37–46 Medline DOI 10.​1006/​bcmd.​2000.​0274 PubMedCrossRef
95.
Casimir CM, Bu-Ghanim HN, Rodaway AR, Bentley DL, Rowe P, Segal AW (1991) Autosomal recessive chronic granulomatous disease caused by deletion at a dinucleotide repeat. Proc Natl Acad Sci U S A 88:2753–2757 Medline DOI 10.​1073/​pnas.​88.​7.​2753 PubMedCrossRef
96.
Iwata M, Nunoi H, Yamazaki H, Nakano T, Niwa H, Tsuruta S, Ohga S, Ohmi S, Kanegasaki S, Matsuda I (1994) Homologous dinucleotide (GT or TG) deletion in Japanese patients with chronic granulomatous disease with p47-phox deficiency. Biochem Biophys Res Commun 199:1372–1377 Medline DOI 10.​1006/​bbrc.​1994.​1382 PubMedCrossRef
97.
Volpp BD, Lin Y (1993) In vitro molecular reconstitution of the respiratory burst in B lymphoblasts from p47-phox deficient chronic granulomatous disease. J Clin Invest 91:201–207 Medline DOI 10.​1172/​JCI116171 PubMedCrossRef
98.
Roesler J, Curnutte JT, Rae J, Barrett D, Patino P, Chanock SJ, Goerlach A (2000) Recombination events between the p47-phox gene and its highly homologous pseudogenes are the main cause of autosomal recessive chronic granulomatous disease. Blood 95:2150–2156 MedlinePubMed
99.
Noack D, Rae J, Cross AR, Ellis BA, Newburger PE, Curnutte JT, Heyworth PG (2001) Autosomal recessive chronic granulomatous disease caused by defects in NCF-1, the gene encoding the phagocyte p47-phox: mutations not arising in the NCF-1 pseudogenes. Blood 97:305–311 Medline DOI 10.​1182/​blood.​V97.​1.​305 PubMedCrossRef
100.
Jurkowska M, Kurenko-Deptuch M, Bal J, Roos D (2004) The search for a genetic defect in Polish patients with chronic granulomatous disease. Arch Immunol Ther Exp (Warsz) 52:441–446 Medline
101.
Görlach A, Lee PL, Roesler J, Hopkins PJ, Christensen B, Green ED, Chanock SJ, Curnutte JT (1997) A p47-phox pseudogene carries the most common mutation causing p47-phox deficient chronic granulomatous disease. J Clin Invest 100:1907–1918 Medline DOI 10.​1172/​JCI119721 PubMedCrossRef
102.
Antonell A, de Luis O, Domingo-Roura X, Pérez-Jurado LA (2005) Evolutionary mechanisms shaping the genomic structure of the Williams–Beuren syndrome chromosomal region at human 7q11.23. Genome Res 9:1179–1188 DOI 10.​1101/​gr.​3944605 CrossRef
103.
Vazquez N, Lehrnbecher T, Chen R, Christensen BL, Gallin JI, Malech H, Holland S, Zhu S, Chanock SJ (2001) Mutational analysis of patients with p47-phox-deficient chronic granulomatous disease: the significance of recombination events between the p47-phox gene (NCF1) and its highly homologous pseudogenes. Exp Hematol 29:234–243 Medline DOI 10.​1016/​S0301-472X(00)00646-9 PubMedCrossRef
104.
Heyworth PG, Noack D, Cross AR (2002) Identification of a novel NCF-1 (p47-phox) pseudogene not containing the signature GT deletion: significance for A47 degrees chronic granulomatous disease carrier detection. Blood 100:1845–1851 Medline DOI 10.​1182/​blood-2002-03-0861 PubMedCrossRef
105.
De Boer M, Singh V, Dekker J, Di Rocco M, Goldblatt D, Roos D (2002) Prenatal diagnosis in two families with autosomal, p47(phox)-deficient chronic granulomatous disease due to a novel point mutation in NCF1. Prenat Diagn 22:235–240 Medline DOI 10.​1002/​pd.​296 PubMedCrossRef
106.
107.
Moreno MU, San José G, Orbe J, Páramo JA, Beloqui O, Díez J, Zalba G (2003) Preliminary characterisation of the promoter of the human p22(phox) gene: identification of a new polymorphism associated with hypertension. FEBS Lett 542:27–31 Medline DOI 10.​1016/​S0014-5793(03)00331-4 PubMedCrossRef
108.
Parkos CA, Dinauer MC, Jesaitis AJ, Orkin SH, Curnutte JT (1989) Absence of both the 91 kD and 22 kD subunits of human neutrophil cytochrome b in two genetic forms of chronic granulomatous disease. Blood 73:1416–1420 MedlinePubMed
109.
Dinauer MC, Pierce EA, Erickson RW, Muhlebach TJ, Messner H, Orkin SH, Seger RA, Curnutte JT (1991) Point mutation in the cytoplasmic domain of the neutrophil p22-phox cytochrome b subunit is associated with a nonfunctional NADPH oxidase and chronic granulomatous disease. Proc Natl Acad Sci U S A 88:11231–11235 Medline DOI 10.​1073/​pnas.​88.​24.​11231 PubMedCrossRef
110.
De Boer M, de Klein A, Hossle JP, Seger R, Corbeel L, Weening RS, Roos D (1992) Cytochrome b558-negative, autosomal recessive chronic granulomatous disease: two new mutations in the cytochrome b558 light chain of the NADPH oxidase (p22-phox). Am J Hum Genet 51:1127–1135 MedlinePubMed
111.
Leusen JH, Bolscher BG, Hilarius PM, Weening RS, Kaulfersch W, Seger RA, Roos D, Verhoeven AJ (1994) 156Pro–>Gln substitution in the light chain of cytochrome b558 of the human NADPH oxidase (p22-phox) leads to defective translocation of the cytosolic proteins p47-phox and p67-phox. J Exp Med 180:2329–2334 Medline DOI 10.​1084/​jem.​180.​6.​2329 PubMedCrossRef
112.
Hossle JP, de Boer M, Seger RA, Roos D (1994) Identification of allele-specific p22-phox mutations in a compound heterozygous patient with chronic granulomatous disease by mismatch PCR and restriction enzyme analysis. Hum Genet 93:437–442 Medline DOI 10.​1007/​BF00201671 PubMedCrossRef
113.
114.
Rae J, Noack D, Heyworth PG, Ellis BA, Curnutte JT, Cross AR (2000) Molecular analysis of 9 new families with chronic granulomatous disease caused by mutations in CYBA, the gene encoding p22-phox. Blood 96:1106–1112 MedlinePubMed
115.
Yamada M, Ariga T, Kawamura N, Ohtsu M, Imajoh-Ohmi S, Ohshika E, Tatsuzawa O, Kobayashi K, Sakiyama Y (2000) Genetic studies of three Japanese patients with p22-phox-deficient chronic granulomatous disease: detection of a possible common mutant CYBA allele in Japan and a genotype–phenotype correlation in these patients. Br J Haematol 108:511–517 Medline DOI 10.​1046/​j.​1365-2141.​2000.​01857.​x PubMedCrossRef
116.
Stasia MJ, Bordigoni P, Martel C, Morel F (2002) A novel and unusual case of chronic granulomatous disease in a child with a homozygous 36-bp deletion in the CYBA gene A220 leading to the activation of a cryptic splice site in intron 4. Hum Genet 110:444–450 Medline DOI 10.​1007/​s00439-002-0720-8 PubMedCrossRef
117.
El Kares R, Barbouche MR, Elloumi-Zghal H, Bejaoui M, Chemli J, Mellouli F, Tebib N, Abdelmoula MS, Boukthir S, Fitouri Z, M’Rad S, Bouslama K, Touiri H, Abdelhak S, Dellagi MK (2006) Genetic and mutational heterogeneity of autosomal recessive chronic granulomatous disease in Tunisia. Hum Genet 51:887–895 DOI 10.​1007/​s10038-006-0039-8 CrossRef
118.
Bakri F, Martel C, El-Khateeb MS, Hamamy HA, Khuri-Bolus N, Mahafzah A, Al-wahadneh AM, Hayajneh WA, Guillot M, Stasia MJ (2008) First report of chronic granulomatous disease in ten Jordanian families. Eur J Clin Invest 38(Suppl. 1):71 Medline
119.
Kleinberg ME, Malech HL, Rotrosen D (1990) The phagocyte 47-kiloDalton cytosolic oxidase protein is an early reactant in activation of the respiratory burst. J Biol Chem 265:15577–15583 MedlinePubMed
120.
Sumimoto H, Hata K, Mizuki K, Ito T, Kage Y, Sakaki Y, Fukumaki Y, Nakamura M, Takeshige K (1996) Assembly and activation of the phagocyte NADPH oxidase. Specific interaction of the N-terminal Src homology 3 domain of p47phox with p22phox is required for activation of the NADPH oxidase. J Biol Chem 271:22152–22158 Medline DOI 10.​1074/​jbc.​271.​36.​22152 PubMedCrossRef
121.
Heyworth PG, Curnutte JT, Nauseef WM, Volpp BD, Pearson DW, Rosen H, Clark RA (1991) Neutrophil nicotinamide adenine dinucleotide phosphate oxidase assembly. Translocation of p47-phox and p67-phox requires interaction between p47-phox and cytochrome b558. J Clin Invest 87:352–356 Medline DOI 10.​1172/​JCI114993 PubMedCrossRef
122.
Eklund EA, Kakar R (1999) Recruitment of CREB-binding protein by PU.1, IFN-regulatory factor-1, and the IFN consensus sequence-binding protein is necessary for IFN-gamma-induced p67phox and gp91phox expression. J Immunol 163:6095–6105 MedlinePubMed
123.
Lindsey S, Huang W, Wang H, Horvath E, Zhu C, Eklund EA (2007) Activation of SHP2 protein-tyrosine phosphatase increases HoxA10-induced repression of the genes encoding gp91(PHOX) and p67(PHOX). J Biol Chem 282:2237–2249 Medline DOI 10.​1074/​jbc.​M608642200 PubMedCrossRef
124.
Ammons MC, Siemsen DW, Nelson-Overton LK, Quinn MT, Gauss KA (2007) Binding of pleomorphic adenoma gene-like 2 to the tumor necrosis factor (TNF)-alpha-responsive region of the NCF2 promoter regulates p67(phox) expression and NADPH oxidase activity. J Biol Chem 282:17941–17952 Medline DOI 10.​1074/​jbc.​M610618200 PubMedCrossRef
125.
de Boer M, Hilarius-Stokman PM, Hossle JP, Verhoeven AJ, Graf N, Kenney RT, Seger R, Roos D (1994) Autosomal recessive chronic granulomatous disease with absence of the 67-kD cytosolic NADPH oxidase component: identification of mutation and detection of carriers. Blood 83:531–536 MedlinePubMed
126.
Tanugi-Cholley LC, Issartel JP, Lunardi J, Freycon F, Morel F, Vignais PV (1995) A mutation located at the 5′ splice junction sequence of intron 3 in the p67phox gene causes the lack of p67phox mRNA in a patient with chronic granulomatous disease. Blood 85:242–249 MedlinePubMed
127.
Nunoi H, Iwata M, Tatsuzawa S, Onoe Y, Shimizu S, Kanegasaki S, Matsuda I (1995) AG dinucleotide insertion in a patient with chronic granulomatous disease lacking cytosolic 67-kD protein. Blood 86:329–33 MedlinePubMed
128.
129.
Leusen JH, de Klein A, Hilarius PM, Ahlin A, Palmblad J, Smith CI, Diekmann D, Hall A, Verhoeven AJ, Roos D (1996) Disturbed interaction of p21-rac with mutated p67-phox causes chronic granulomatous disease. J Exp Med 184:1243–1249 Medline DOI 10.​1084/​jem.​184.​4.​1243 PubMedCrossRef
130.
Aoshima M, Nunoi H, Shimazu M, Shimizu S, Tatsuzawa O, Kenney RT, Kanegasaki S (1996) Two-exon skipping due to a point mutation in p67-phox-deficient chronic granulomatous disease. Blood 88:1841–1845 MedlinePubMed
131.
Bonizzato A, Russo MP, Donini M, Dusi S (1997) Identification of a double mutation (D160V–K161E) in the p67phox gene of a chronic granulomatous disease patient. Biochem Biophys Res Commun 231:861–863 Medline DOI 10.​1006/​bbrc.​1997.​6204 PubMedCrossRef
132.
Patino PJ, Rae J, Noack D, Erickson R, Ding J, de Olarte DG, Curnutte JT (1999) Molecular characterization of autosomal recessive chronic granulomatous disease caused by a defect of the nicotinamide adenine dinucleotide phosphate (reduced form) oxidase component p67-phox. Blood 94:2505–2514 MedlinePubMed
133.
Noack D, Rae J, Cross AR, Muñoz J, Salmen S, Mendoza JA, Rossi N, Curnutte JT, Heyworth PG (1999) Autosomal recessive chronic granulomatous disease caused by novel mutations in NCF-2, the gene encoding the p67-phox component of phagocyte NADPH oxidase. Hum Genet 105:460–467 Medline DOI 10.​1007/​s004390051131 PubMedCrossRef
134.
135.
136.
Grizot S, Fieschi F, Dagher MC, Pebay-Peyroula E (2001) The active N-terminal region of p67phox. Structure at 1.8 A resolution and biochemical characterizations of the A128V mutant implicated in chronic granulomatous disease. J Biol Chem 276:21627–21631 Medline DOI 10.​1074/​jbc.​M100893200 PubMedCrossRef
137.
Lapouge K, Smith SJ, Walker PA, Gamblin SJ, Smerdon SJ, Rittinger K (2000) Structure of the TPR domain of p67phox in complex with Rac.GTP. Mol Cell 6:899–907 MedlinePubMed
138.
Borgato L, Bonizzato A, Lunardi C, Dusi S, Andrioli G, Scarperi A, Corrocher R (2001) A 1.1-kb duplication in the p67-phox gene causes chronic granulomatous disease. Hum Genet 108:504–510 Medline DOI 10.​1007/​s004390100526 PubMedCrossRef
139.
140.
Tsunawaki S, Yoshikawa K (2002) Relationships of p40(phox) with p67(phox) in the activation and expression of the human respiratory burst NADPH oxidase. J Biochem 128:777–783
141.
142.
Martire B, Rondelli R, Soresina A, Pignata C, Broccoletti T, Finocchi A, Rossi P, Gattorno M, Rabusin M, Azzari C, Dellepiane RM, Pietrogrande MC, Trizzino A, Di Bartolomeo P, Martino S, Carpino L, Cossu F, Locatelli F, Maccario R, Pierani P, Putti MC, Stabile A, Notarangelo LD, Ugazio AG, Plebani A, De Mattia D (2008) Links clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. IPINET (Italian Network for Primary Immunodeficiencies) Clin Immunol 126:155–164 Medline DOI 10.​1016/​j.​clim.​2007.​09.​008 PubMedCrossRef
143.
Marciano BE, Wesley R, De Carlo ES, Anderson VL, Barnhart LA, Darnell D, Malech HL, Gallin JI, Holland SM (2004) Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin Infect Dis 39(5):692–699 Medline DOI 10.​1086/​422993 PubMedCrossRef
144.
145.
Margolis DM, Melnick DA, Alling DW, Gallin JI (1990) Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis 162(3):723–726 MedlinePubMed
146.
147.
148.
Mouy R, Veber F, Blanche S, Donadieu J, Brauner R, Levron JC, Griscelli C, Fischer A (1994) Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. J Pediatr 125:998–1003 Medline DOI 10.​1016/​S0022-3476(05)82023-2 PubMedCrossRef
149.
Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, Eisenstein EM, Turner ML, DeCarlo ES, Starling JM, Holland SM (2003) Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 348(24):2416–2422 Medline DOI 10.​1056/​NEJMoa021931 PubMedCrossRef
150.
151.
The International Chronic Granulomatous Disease Cooperative Study Group (1991) A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 324(8):509–516 Feb 21 Comment in: N Engl J Med. 1991 Nov 21;325(21):1516–1517, Medline
152.
Ezekowitz RA, Orkin SH, Newburger PE (1987) Recombinant interferon gamma augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease. J Clin Invest 80(4):1009–1016 Medline DOI 10.​1172/​JCI113153 PubMedCrossRef
153.
Newburger PE, Ezekowitz RA (1988) Cellular and molecular effects of recombinant interferon gamma in chronic granulomatous disease. Hematol Oncol Clin North Am 2(2):267–276 MedlinePubMed
154.
Weening RS, Leitz GJ, Seger RA (1995) Recombinant human interferon-gamma in patients with chronic granulomatous disease—European follow up study. Eur J Pediatr 154(4):295–298 MedlinePubMed
155.
Jackson SH, Miller GF, Segal BH, Mardiney M 3rd, Domachowske JB, Gallin JI, Holland SM (2001) IFN-gamma is effective in reducing infections in the mouse model of chronic granulomatous disease (CGD). J Interferon Cytokine Res 21(8):567–573 Medline DOI 10.​1089/​1079990015254782​1 PubMedCrossRef
156.
157.
Horwitz ME, Barrett AJ, Brown MR, Carter CS, Childs R, Gallin JI, Holland SM, Linton GF, Miller JA, Leitman SF, Read EJ, Malech HL (2001) Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med 344(12):881–888 Comment in: N Engl J Med 344(12):926–927, 2001, Mar 22, Medline DOI 10.​1056/​NEJM200103223441​203 PubMedCrossRef
158.
Seger RA, Gungor T, Belohradsky BH, Blanche S, Bordigoni P, Di Bartolomeo P, Flood T, Landais P, Müller S, Ozsahin H, Passwell JH, Porta F, Slavin S, Wulffraat N, Zintl F, Nagler A, Cant A, Fischer A (2002) Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience. 1985-2000. Blood 100(13):4344–4350 Medline DOI 10.​1182/​blood-2002-02-0583
159.
160.
Goudemand J, Anssens R, Delmas-Marsalet Y, Farriaux JP, Fontaine G (1976) Attempt to treat a case of chronic familial granulomatous disease by allogenic bone marrow transplantation. Arch Fr Pediatr 33:121–129 MedlinePubMed
161.
Stein S, Siler U, Ott MG, Seger R, Grez M (2006) Gene therapy for chronic granulomatous disease. Curr Opin Mol Ther 8:415–422 MedlinePubMed
162.
Del Giudice I, Iori AP, Mengarelli A, Testi AM, Romano A, Cerretti R, Macrì F, Iacobini M, Arcese W (2003) Allogeneic stem cell transplant from HLA-identical sibling for chronic granulomatous disease and review of the literature. Ann Hematol 82(3):189–192 MedlinePubMed
163.
Sastry J, Kakakios A, Tugwell H, Shaw PJ (2006) Links allogeneic bone marrow transplantation with reduced intensity conditioning for chronic granulomatous disease complicated by invasive Aspergillus infection. Pediatr Blood Cancer 47:327–329 Medline DOI 10.​1002/​pbc.​20865 PubMedCrossRef
164.
Thrasher A, Chetty M, Casimir C, Segal AW (1992) Restoration of superoxide generation to a chronic granulomatous disease-derived B-cell line by retrovirus mediated gene transfer. Blood 80:1125–1129 MedlinePubMed
165.
Maly FE, Schuerer-Maly CC, Quilliam L, Cochrane CG, Newburger PE, Curnutte JT, Gifford M, Dinauer MC (1993) Restitution of superoxide generation in autosomal cytochrome-negative chronic granulomatous disease (A22(0) CGD)-derived B lymphocyte cell lines by transfection with p22phax cDNA. J Exp Med 178:2047–2053 Medline DOI 10.​1084/​jem.​178.​6.​2047 PubMedCrossRef
166.
Porter CD, Parkar MH, Levinsky RJ, Collins MK, Kinnon C (1993) X-linked chronic granulomatous disease: correction of NADPH oxidase defect by retrovirus-mediated expression of gp91-phox. Blood. 82:2196–2202 MedlinePubMed
167.
168.
Sekhsaria S, Gallin JI, Linton GF, Mallory RM, Mulligan RC, Malech HL (1993) Peripheral blood progenitors as a target for genetic correction of p47phox-deficient chronic granulomatous disease. Proc Natl Acad Sci U S A 90:7446–7450 Medline DOI 10.​1073/​pnas.​90.​16.​7446 PubMedCrossRef
169.
Li F, Linton GF, Sekhsaria S, Whiting-Theobald N, Katkin JP, Gallin JI, Malech HL (1994) CD34+ peripheral blood progenitors as a target for genetic correction of the two flavocytochrome b558 defective forms of chronic granulomatous disease. Blood 84:53–58 MedlinePubMed
170.
Becker S, Wasser S, Hauses M, Hossle JP, Ott MG, Dinauer MC, Ganser A, Hoelzer D, Seger R, Grez M (1998) Correction of respiratory burst activity in X-linked chronic granulomatous cells to therapeutically relevant levels after gene transfer into bone marrow CD34+ cells. Hum Gene Ther 9:1561–1570 Medline DOI 10.​1089/​hum.​1998.​9.​11-1561 PubMedCrossRef
171.
Weil WM, Linton GF, Whiting-Theobald N, Vowells SJ, Rafferty SP, Li F, Malech HL (1997) Genetic correction of p67phox deficient chronic granulomatous disease using peripheral blood progenitor cells as a target for retrovirus mediated gene transfer. Blood 89:1754–1761 MedlinePubMed
172.
Ding C, Kume A, Bjorgvinsdottir H, Hawley RG, Pech N, Dinauer MC (1996) High-level reconstitution of respiratory burst activity in a human X-linked chronic granulomatous disease (X-CGD) cell line and correction of murine X-CGD bone marrow cells by retroviral mediated gene transfer of human gp91phox. Blood 88:1834–1840 MedlinePubMed
173.
Bjorgvinsdottir H, Ding C, Pech N, Gifford MA, Li LL, Dinauer MC (1997) Retroviral-mediated gene transfer of gp91phox into bone marrow cells rescues defect in host defense against Aspergillus fumigatus in murine X-linked chronic granulomatous disease. Blood 89:41–48 MedlinePubMed
174.
Mardiney M, Jackson SH, Spratt SK, Li F, Holland SM, Malech HL (1997) Enhanced host defense after gene transfer in the murine p47phox deficient model of chronic granulomatous disease. Blood 89:2268–2275 MedlinePubMed
175.
Dinauer MC, Li LL, Björgvinsdóttir H, Ding C, Pech N (1999) Long-term correction of phagocyte NADPH oxidase activity by retroviral-mediated gene transfer in murine X-linked chronic granulomatous disease. Blood 94:914–922 MedlinePubMed
176.
Dinauer MC, Gifford MA, Pech N, Li LL, Emshwiller P (2001) Variable correction of host defense following gene transfer and bone marrow transplantation in murine X-linked chronic granulomatous disease. Blood 97:3738–3745 Medline DOI 10.​1182/​blood.​V97.​12.​3738 PubMedCrossRef
177.
178.
Schwickerath O, Brouns G, Thrasher A, Kinnon C, Roes J, Casimir C (1997) Enhancer-deleted retroviral vectors restore high levels of superoxide generation in a mouse model of CGD. J Gene Med 6:603–615 DOI 10.​1002/​jgm.​557 CrossRef
179.
Schneider SD, Rusconi S, Seger RA, Hossle JP (1997) Adenovirus-mediated gene transfer into monocyte-derived macrophages of patients with X-linked chronic granulomatous disease: ex vivo correction of deficient respiratory burst. Gene Ther 4:524–532 Medline DOI 10.​1038/​sj.​gt.​3300432 PubMedCrossRef
180.
Trasher AJ, de Alwis M, Casimir CM, Kinnon C, Page K, Lebkowski J, Segal AW, Levinsky RJ (1995) Generation of recombinant adeno-associated virus (rAAV) from an adenoviral vector and functional reconstitution of the NADPH-oxidase. Gene Ther 2:481–485 Medline
181.
Li LL, Dinauer M (1998) Reconstitution of NADPH oxidase activity in human X-linked chronic granulomatous disease myeloid cells after stable gene transfer using a recombinant adeno-associated virus 2 vector. Blood Cells Mol Dis 24:522–538 Medline DOI 10.​1006/​bcmd.​1998.​0216 PubMedCrossRef
182.
Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A (2003) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348:255–256 Medline DOI 10.​1056/​NEJM200301163480​314 PubMedCrossRef
183.
184.
Ott MG, Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kühlcke K, Schilz A, Kunkel H, Naundorf S, Brinkmann A, Deichmann A, Fischer M, Ball C, Pilz I, Dunbar C, Du Y, Jenkins NA, Copeland NG, Lüthi U, Hassan M, Thrasher AJ, Hoelzer D, von Kalle C, Seger R, Grez M (2006) Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12:386–388 Medline DOI 10.​1038/​nm1393 CrossRef
185.
Sokolic RA, Sekhsaria S, Sugimoto Y, Whiting-Theobald N, Linton GF, Li F, Gottesman MM, Malech HL (1996) A bicistronic retrovirus vector containing a picornavirus internal ribosome entry site allows for correction of X-linked CGD by selection for MDR1 expression. Blood 87:42–50 MedlinePubMed
186.
Iwata M, Nunoi H, Matsuda I, Kanegasaki S, Tsuruo T, Sugimoto Y (1998) Drug-selected complete restoration of superoxide generation in Epstein–Barr virus-transformed B cells from p47phox-deficient chronic granulomatous disease patients by using a bicistronic retrovirus vector encoding a human multi-drug resistance gene (MDR1) and the p47phox gene. Hum Genet 103:419–423 Medline DOI 10.​1007/​s004390050844 PubMedCrossRef
187.
Naumann N, De Ravin SS, Choi U, Moayeri M, Whiting-Theobald N, Linton GF, Ikeda Y, Malech HL (2007) Simian immunodeficiency virus lentivector corrects human X-linked chronic granulomatous disease in the NOD/SCID mouse xenograft. Gene Ther 14(21):1513–1524 Epub 2007 Aug 30, Medline DOI 10.​1038/​sj.​gt.​3303010 PubMedCrossRef
188.
Brenner S, Whiting-Theobald NL, Linton GF, Holmes KL, Anderson-Cohen M, Kelly PF, Vanin EF, Pilon AM, Bodine DM, Horwitz ME, Malech HL (2003) Concentrated RD114-pseudotyped MFGS-gp91phox vector achieves high levels of functional correction of the chronic granulomatous disease oxidase defect in NOD/SCID/beta-microglobulin−/− repopulating mobilized human peripheral blood CD34+ cells. Blood 102:2789–2797 Medline DOI 10.​1182/​blood-2002-05-1482 PubMedCrossRef
189.
Malech HL, Maples PB, Whiting-Theobald N, Linton GF, Sekhsaria S, Vowells SJ, Li F, Miller JA, DeCarlo E, Holland SM, Leitman SF, Carter CS, Butz RE, Read EJ, Fleisher TA, Schneiderman RD, Van Epps DE, Spratt SK, Maack CA, Rokovich JA, Cohen LK, Gallin JI (1997) Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A 94:12133–12338 Medline DOI 10.​1073/​pnas.​94.​22.​12133 PubMedCrossRef
190.
Malech HL, Bauer TR Jr, Hickstein DD (1997) Prospects for gene therapy of neutrophil defects. Semin Hematol 34:355–361 MedlinePubMed
191.
192.
Malech HL, Choi U, Brenner S (2004) Progress toward effective gene therapy for chronic granulomatous disease. Jpn J Infect Dis 57:S27–S28 MedlinePubMed
193.
194.
Ott MG, Koehl U, Sadat MA, Merget-Millitzer H, Stein S, Saulnier S, Hossle JP, Dinauer MC, Seger R, Hoelzer D, Grez M (2003) Gene therapy of chronic granulomatous disease: results from pre-clinical and phase I clinical studies. Mol Ther 7(5 Suppl):S408
195.
Siler U, Ott MG, Stein S, Karaus E, Rutishauser M, Wenk C, Hoelzer D, Grez M, Seger R (2005) Chronic granulomatous disease gene therapy functionally corrects the phenotype of polymorphonuclear leukocytes (PMN). Mol Ther 11(Suppl 1):S129 DOI 10.​1016/​j.​ymthe.​2005.​06.​335 CrossRef
196.
197.
198.
199.
Metadaten
Titel
Genetics and immunopathology of chronic granulomatous disease
verfasst von
Marie José Stasia
Xing Jun Li
Publikationsdatum
01.07.2008
Verlag
Springer-Verlag
Erschienen in
Seminars in Immunopathology / Ausgabe 3/2008
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-008-0121-8

Weitere Artikel der Ausgabe 3/2008

Seminars in Immunopathology 3/2008 Zur Ausgabe

Review

Nox enzymes and oxidative stress in the immunopathology of the gastrointestinal tract

Review

Priming of the neutrophil NADPH oxidase activation: role of p47phox phosphorylation and NOX2 mobilization to the plasma membrane

Review

NOX enzymes and Toll-like receptor signaling

Letter to the Editor

Reply to the remarks by Joachim Roesler on the article Genetics and immunopathology of chronic granulomatous disease

Letter to the Editor

Remarks on the article Genetics and immunopathology of chronic granulomatous disease by Marie José Stasia and Xing Jun Li

Review

Hyperinflammation in chronic granulomatous disease and anti-inflammatory role of the phagocyte NADPH oxidase

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise